Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.

Hermanowski T, Kowalik E, Jakubczyk M, Niewada M
Record ID 32009100094
English
Authors' methods: Economic evaluation
Details
Project Status: Completed
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Poland
MeSH Terms
  • Antihypertensive Agents
  • Costs and Cost Analysis
  • Poland
  • Epoprostenol
  • Hypertension, Pulmonary
  • Iloprost
  • Vasodilator Agents
Contact
Organisation Name: Agency for Health Technology Assessment and Tariff System
Contact Address: Agency for Health Technology Assessment in Poland (AHTAPol), 22 Lotnik w Av., Warsaw, POLAND 02-668:Tel: +48 22 56 67 200 Fax: +48 22 56 67 202 Contact: Tomasz Garbaty
Contact Name: sekretariat@aotm.gov.pl
Contact Email: sekretariat@aotm.gov.pl
Copyright: Agency for Health Technology Assessment in Poland (AHTAPol)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.